Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC is a phase 2, randomised interventional study registered as NCT07646639 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 122 participants, started 2026-05-20 and due to reach its primary completion in 2028-12-31. Interventions recorded: Sintilimab + IL-2 Combined with CAPOX; Short-course low-dose radiotherapy; Short-course standard-dose radiotherapy. Conditions listed: Rectal Cancer; Radiotherapy. Primary outcome: Complete remission. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma with the distal margin of the tumor located within 12 cm of the anal verge". Sites: China. No results are recorded here; the registry entry is the source.